Fiorica F, et al. - In pretreated, advanced, or metastatic lung cancer patients, researchers conducted this retrospective analysis to assess the addition of radiotherapy (RT) to an immune checkpoint inhibitor (nivolumab) for activity and feasibility. For this investigation, 35 consecutive patients (30 men and 5 women) were retrospectively identified, who received nivolumab for pretreated non–small cell lung cancer (NSCLC) between March 2015 to December 2016. The study findings suggested that RT and nivolumab could be combined, with an advantage seen for overall survival and progression-free survival, without an increase in acute toxicities in pretreated advanced NSCLC patients. No difference was seen in adverse events.